General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-07-24 | 2024-06 | 0.99 | N/A | N/A | N/A |
2024-05-01 | 2024-03 | 0.94 | 1.09 | 0.15 | 15.96% |
2024-01-31 | 2023-12 | 0.76 | 0.72 | -0.04 | -5.26% |
2023-11-01 | 2023-09 | 1.09 | 1.26 | 0.17 | 15.60% |
2023-07-26 | 2023-06 | 0.85 | 0.97 | 0.12 | 14.12% |
2023-04-26 | 2023-03 | 0.85 | 0.9 | 0.05 | 5.88% |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2022-03-22 | Bancroft (Charles A) | 9.06K | Bought | |
2022-10-11 | Barron (Hal V) | 433.45K | Bought | |
2022-03-22 | Beal (Anne) | 698.00 | Bought | |
2022-07-18 | BlackRock Inc. | 838.94K | Holding | |
2022-07-26 | Conrad (D) | 16.45K | Bought | |
2022-03-22 | Dietz (Hal) | 329.00 | Bought |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Dodge & Cox Inc | 69.61M | 2.48B | 3.40% |
2023-06-29 | FMR, LLC | 16.81M | 599.05M | 0.82% |
2023-06-29 | Fisher Asset Management, LLC | 13.82M | 492.71M | 0.68% |
2023-06-29 | Price (T.Rowe) Associates Inc | 13.03M | 464.46M | 0.64% |
2023-09-29 | JTC Employer Solutions Trusteee Ltd | 12.44M | 451.11M | 0.61% |
2023-06-29 | Primecap Management Company | 11.77M | 419.55M | 0.57% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Dodge & Cox Stock Fund | 49.78M | 1.77B | 2.43% |
2023-06-29 | Vanguard/Primecap Fund | 8.47M | 301.85M | 0.41% |
2023-06-29 | Dodge & Cox Balanced Fund | 5.59M | 199.41M | 0.27% |
2023-06-29 | Price (T.Rowe) International Value Equity Trust | 3.27M | 116.65M | 0.16% |
2023-07-30 | Price (T.Rowe) International Value Equity Fund | 3.15M | 112.07M | 0.15% |
2023-07-30 | Price (T.Rowe) Overseas Stock Fund | 3.06M | 108.92M | 0.15% |
Dividend | Date |
---|---|
0.37619 | 2024-05-16 |
0.40606 | 2024-02-22 |
0.33978 | 2023-11-16 |
0.36126 | 2023-08-17 |
0.34751 | 2023-05-18 |
0.333 | 2023-02-23 |
Split | Date |
---|---|
1226 : 1000 | 2022-07-22 |
4 : 5 | 2022-07-19 |
2 : 1 | 1991-11-12 |
2 : 1 | 1986-01-27 |
2 : 1 | 1983-02-23 |
2 : 1 | 1983-02-22 |
$GSK I am obvi not gonna predict a bottom, but I think this is near (or at) a good place to buy in, or use to CA down, given fair value estimate of $50. Reasonable guess is they can hold Zantac lawsuit losses to $1bil or less. If they do, which we should know by the end of q1-2023, GSK could rise 20% (or more) without even breathing hard. Is it a gamble? Yeah. Is the fear of a $10billion loss already baked in to the price and the 7-9% cut in PT by chase, JPM and others? I think so. Comments?
Hi I’m new to this stock but did this company just cure cancer? $GSK
THE SNAKES ARE COMING OUT.
The masks begin to fall off ! “The Chinese biological laboratory in Wuhan is owned by GlaxoSmithKline, which (accidentally) owns Pfizer!” (the one who makes the vaccine against the virus which (accidentally) started at the Wuhan Biological Lab and which was (accidentally) funded by Dr. Fauci, who (accidentally) promotes the vaccine !
"GlaxoSmithKline is (accidentally) managed by the finance division of Black Rock, which (accidentally) manages the finances of the Open Foundation Company (Soros Foundation), which (accidentally) manages the French AXA !”
Soros (accidentally) owns the German company Winterthur, which (accidentally) built a Chinese laboratory in Wuhan and was bought by the German Allianz, which (coincidentally) has Vanguard as a shareholder, who (coincidentally) is a shareholder of Black Rock, which (coincidentally) controls central banks and manages about a third of global investment capital. “Black Rock" is also (coincidentally) a major shareholder of MICROSOFT, owned by Bill Gates, who (coincidentally) is a shareholder of Pfizer (which - remember ? sells a miracle vaccine) and (coincidentally) is now the first sponsor of the WHO !
Now you understand how a dead bat sold in a wet market in China has infected the WHOLE PLANET !""
Now you know pass it on until whole world knows.
$OPTI is expected to be listed on the nasdaq, in the 1st quarter. This means it will have to go to at least 2 dollars a share. Great things are happening. Get in, before you wished you would have. Big names, like Kevin Harrington, from Shark Tank & a former Amazon big wig are on the board.
$SAVA - A second opinion
*
If you have been following Cassava and their Alzheimers drug PTI-125, you will know that 1 of 2 trial endpoints was not recently met, sending the stock down almost 80%. But, I think the exodus was premature. Here is why:
Per the companys press release, one endpoint WAS MET:
A secondary endpoint of CSF levels of IL1-beta, a core biomarker of neuroinflammation from baseline to day 28, was met, Cassava said. The drug was also found to be safe and well-tolerated.
Per NIH, neuro inflammation is the CORE issue with Alzheimers:
Inflammation in Alzheimer's disease (AD) has emerged as a central pathology that likely plays a role in onset and progression of the disease
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214864/
Cycling back to Cassavas press release, they state:
CSF levels of IL1-beta, a core biomarker of neuroinflammation ... was met
To reiterate the NIH definition, Neuro Inflammation is core to the onset and progression of Alzheimers. At some point, Cassava IS going to cycle back around to the secondary endpoint (neuro inflammation), and realize that ALONE constitutes an ALZHEIMER DRUG THAT WORKS.
In this case, traders were SO tuned into the word miss that they MISSED something EXTREMELY IMPORTANT -> The efficacy of PTI-125 towards Neuro Inflammation, in Alzheimers (ALONE), makes it A BLOCKBUSTER DRUG!
$SAVA - A second opinion
*
If you have been following Cassava and their Alzheimers drug PTI-125, you will know that 1 of 2 endpoints was not recently met, sending the stock down almost 80%. But, I think the exodus was premature. Here is why:
Per the companys press release, one endpoint WAS MET:
A secondary endpoint of CSF levels of IL1-beta, a core biomarker of neuroinflammation from baseline to day 28, was met, Cassava said. The drug was also found to be safe and well-tolerated.
Per NIH, here is the CORE issue with Alzheimers:
Inflammation in Alzheimer's disease (AD) has emerged as a central pathology that likely plays a role in onset and progression of the disease
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214864/
Cycling back to Cassavas press release, they state:
CSF levels of IL1-beta, a core biomarker of neuroinflammation ... was met
To reiterate the NIH definition, Neuro Inflammation is core to the onset and progression of Alzheimers. At some point, Cassava IS going to cycle back around to the secondary endpoint (neuro inflammation), and realize that ALONE constitutes an ALZHEIMER DRUG THAT WORKS.
In this case, traders were SO tuned into the word miss that they MISSED something EXTREMELY IMPORTANT. That the efficacy of PTI-125 towards Neuro Inflammation, in Alzheimers (ALONE), makes it A BLOCKBUSTER DRUG!